Welcome to our dedicated page for Xencor SEC filings (Ticker: XNCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Xencor, Inc. filings document the regulatory record for a clinical-stage biopharmaceutical company developing engineered antibody candidates for cancer, autoimmune disease and inflammatory disease. Its Form 8-K disclosures cover financial results, Regulation FD presentations for XmAb942, XmAb412 and the TL1A portfolio, royalty-related disclosures for Ultomiris, and material developments involving collaboration and license agreements.
Proxy materials describe board elections, executive compensation, equity-award information, stockholder voting matters and governance policies. Additional current reports address compensatory arrangements, including executive severance policy disclosures, alongside capital resources and operating-runway information furnished with financial updates.
Xencor Inc director Ellen Feigal reported an open-market sale of 6,843 shares of Common Stock at $13.06 per share. The transaction was executed on June 18, 2026 pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on June 26, 2025. Following this sale, Feigal holds 12,340 shares directly.
Xencor, Inc. held its 2026 Annual Meeting of Stockholders, with 63,939,410 common shares present or represented by proxy, equal to approximately 86.26% of the 74,127,372 shares outstanding and entitled to vote as of April 17, 2026.
Stockholders elected nine directors to serve until the 2027 Annual Meeting and ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. They also approved an amendment and restatement of the 2023 Equity Incentive Plan, increasing authorized shares reserved for issuance by 4,000,000 shares, and approved on an advisory, non-binding basis the compensation of the company’s named executive officers.
Xencor Inc director Kevin Charles Gorman reported an open-market sale of 7,527 shares of Xencor common stock. The shares were sold at an average price of $12.31 per share. This trade was executed under a 10b5-1 trading plan adopted on June 27, 2025. Following the sale, Gorman directly holds 11,378 Xencor shares.
Xencor Inc director Kurt A. Gustafson reported an open-market sale of company stock. He sold 5,474 shares of Common Stock at a price of $12.31 per share. After this transaction, he directly holds 14,709 Xencor shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person.
Xencor Inc director Richard J. Ranieri reported an open-market sale of company stock. On June 15, 2026, he sold 5,474 shares of Common Stock at an average price of $12.31 per share under a pre-arranged Rule 10b5-1 trading plan adopted on June 26, 2025. Following this transaction, he directly holds 13,709 shares.
Xencor Inc director Alan Bruce Montgomery reported an open-market sale of Xencor common stock. On June 15, 2026, he sold 5,064 shares of Common Stock at $12.31 per share. After this transaction, he directly owned 15,547 shares of Xencor common stock.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 4, 2026, indicating the timing of the trade was set in advance rather than decided spontaneously.